Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $2.0 million.

  • Biodesix's Other Accumulated Expenses fell 2365.35% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 2365.35%. This contributed to the annual value of $2.4 million for FY2024, which is 1730.5% down from last year.
  • Latest data reveals that Biodesix reported Other Accumulated Expenses of $2.0 million as of Q3 2025, which was down 2365.35% from $2.3 million recorded in Q2 2025.
  • Biodesix's 5-year Other Accumulated Expenses high stood at $4.6 million for Q1 2021, and its period low was $1.5 million during Q1 2023.
  • Its 5-year average for Other Accumulated Expenses is $2.6 million, with a median of $2.4 million in 2023.
  • Per our database at Business Quant, Biodesix's Other Accumulated Expenses plummeted by 4508.56% in 2023 and then soared by 13444.07% in 2024.
  • Over the past 5 years, Biodesix's Other Accumulated Expenses (Quarter) stood at $2.8 million in 2021, then fell by 16.31% to $2.3 million in 2022, then increased by 24.06% to $2.9 million in 2023, then fell by 17.31% to $2.4 million in 2024, then fell by 14.65% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.3 million for Q2 2025, and $2.2 million during Q1 2025.